Online inquiry

IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6945MR)

This product GTTS-WQ6945MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA), Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6945MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3272MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ819MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ13166MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ12282MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ1111MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ824MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ11336MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ5260MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CB-6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW